Investors Sell Shares of Pfizer (PFE) on Strength (PFE)

Saturday, June 30 2018

Investors Sell Shares of Pfizer (PFE) on Strength (PFE)

Posted by Anna Parker Philips on Jun 30th, 2018 // No Comments
Investors sold shares of Pfizer Inc. (NYSE:PFE) on strength during trading hours on Thursday. $53.59 million flowed into the stock on the tick-up and $119.88 million flowed out of the stock on the tick-down, for a money net flow of $66.29 million out of the stock. Of all companies tracked, Pfizer had the 0th highest net out-flow for the day. Pfizer traded up $0.15 for the day and closed at $36.36
A number of equities research analysts have recently weighed in on PFE shares. Credit Suisse Group set a $39.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a report on Monday, June 11th. Jefferies Financial Group set a $38.00 price objective on shares of Pfizer and gave the stock a “hold” rating in a report on Friday, April 13th. BMO Capital Markets set a $43.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a report on Tuesday, March 6th. Zacks Investment Research lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Thursday, April 12th. Finally, Barclays lowered shares of Pfizer from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $41.00 to $38.00 in a report on Thursday, April 5th. Three research analysts have rated the stock with a sell rating, twelve have given a hold rating and ten have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $40.27. Get Pfizer alerts:
The company has a current ratio of 1.27, a quick ratio of 0.98 and a debt-to-equity ratio of 0.45. The stock has a market cap of $216.45 billion, a PE ratio of 13.69, a price-to-earnings-growth ratio of 1.81 and a beta of 0.91. Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, May 1st. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.03. The business had revenue of $12.91 billion for the quarter, compared to the consensus estimate of $13.14 billion. Pfizer had a net margin of 41.29% and a return on equity of 25.29%. The company’s quarterly revenue was up 1.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.69 EPS. analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 4th. Shareholders of record on Friday, August 3rd will be given a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 3.75%. The ex-dividend date of this dividend is Thursday, August 2nd. Pfizer’s payout ratio is currently 51.32%.
In other Pfizer news, CEO Ian C. Read sold 132,312 shares of the business’s stock in a transaction on Tuesday, May 1st. The shares were sold at an average price of $36.01, for a total transaction of $4,764,555.12. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink . Also, EVP Laurie J. Olson sold 19,000 shares of the business’s stock in a transaction on Wednesday, June 6th. The shares were sold at an average price of $36.45, for a total transaction of $692,550.00. Following the transaction, the executive vice president now directly owns 98,644 shares in the company, valued at $3,595,573.80. The disclosure for this sale can be found here . Over the last three months, insiders have sold 156,535 shares of company stock worth $5,647,222. Insiders own 0.06% of the company’s stock.
Hedge funds have recently made changes to their positions in the company. Ballew Advisors Inc bought a new stake in shares of Pfizer during the 1st quarter valued at $102,000. Earnest Partners LLC bought a new stake in shares of Pfizer during the 4th quarter valued at $105,000. First Dallas Securities Inc. bought a new stake in shares of Pfizer during the 4th quarter valued at $118,000. Woodard & Co. Asset Management Group Inc. ADV bought a new stake in shares of Pfizer during the 4th quarter valued at $118,000. Finally, Delpha Capital Management LLC bought a new stake in shares of Pfizer during the 4th quarter valued at $126,000. Hedge funds and other institutional investors own 69.44% of the company’s stock.
About Pfizer
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care. Receive News & Ratings for Pfizer analysts' ratings for Pfizer and related companies daily email newsletter .